ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

DePinho’s Handling Of MD Anderson Tenure Dispute Triggers Formal Investigation by AAUP

July 18, 2014

Controversial Toxicology Protocol Is “Getting The Information We Need;” Additionally Revision Made

March 2, 1984

Construction Needs From NCI Said $40 Million Year For Four Years

June 9, 1978

House committee asks GAO to investigate Klausner-era NCI contract with Harvard University.

September 9, 2005

House subcommittee proposes 2.8 percent increase for NIH, NCI.

July 16, 2004

Chemoprevention Concept Approved By DCPC Bard Uses Biological Markers To Assess Risk Modulation

September 27, 1985